If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Swiss drugmakers not contacted by China after GSK probe

Wed, 17th Jul 2013 06:04

ZURICH, July 17 (Reuters) - Swiss drugmakers Novartis and Roche said on Wednesday they were notaware they were under scrutiny by Chinese authorities in lightof the ongoing investigation into British drugmakerGlaxoSmithKline on allegations of bribery.

"We have not been contacted by Chinese authorities on thismatter," Novartis Chief Executive Joseph Jimenez told reporterson a conference call.

Chinese police on Monday accused British drugmakerGlaxoSmithKline of channelling bribes to Chinese officials anddoctors through travel agencies to boost sales illegally andraise the price of its medicines in the country.

Fellow Swiss drugmaker Roche also said it had notbeen approached by officials in the country.

"We are not aware of any anti-corruption probes in Chinaagainst Roche. We are committed to ensure the same highstandards of compliance for all Roche employees worldwide," aspokesman said in a statement.

Related Shares

More News
9 May 2024 15:51

UK dividends calendar - next 7 days

8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a...

2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.